Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New cell therapy trial offers hope for lymphoma patients Who've run out of options

NCT ID NCT07283679

Summary

This early-stage trial is testing whether a combination of three treatments can help control B-cell lymphoma that has returned or stopped responding to previous therapies. The treatment involves giving patients specially engineered natural killer (NK) cells from umbilical cord blood along with two antibody drugs. Researchers will study 30 adults with lymphoma that has failed at least two prior treatments or stem cell transplant, focusing first on safety and finding the right dose.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The University of Texas M. D. Anderson Cancer Center

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.